Nuvelo stops catheter occlusion Phase II

NUVO closed enrollment early in its double-blind, placebo-controlled Phase II trial of alfimeprase to treat venous catheter occlusion. The company said that data from a DSMB review announced last month are "more than sufficient to guide" further development. The trial dosed a total of 56 patients who received either 0.3 mg, 1.0 mg and 3.0 mg of alfimeprase or Activase alteplase tissue plasminogen activator (tPA) from Genentech (DNA). The company had planned to enroll about 100 patients in the study. ...